Moreover, Roy et al. found that HMGB1 levels were elevated in bortezomib-resistant myeloma cells and that bortezomib and lycorine effectively resensitized refractory cells to bortezomib. This evidence concerns the gene HMGB1 and plasma cell myeloma.